Dose-finding Study of Hexaminolevulinate (HAL) Photodynamic Therapy (PDT) to Treat Cervical Neoplasia
Information source: PhotoCure
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Cervical Intraepithelial Neoplasia
Intervention: HAL 5% with illumination (Drug); HAL 1% with illumination (Drug); HAL 0.2% with illumination (Drug); Placebo ointment without illumination (Drug)
Phase: Phase 2
Status: Completed
Sponsored by: PhotoCure Official(s) and/or principal investigator(s): Peter Hillemanns, MD, PhD, Principal Investigator, Affiliation: University Hospital Hannover
Summary
An effective and safe medical therapy would be most welcome to reduce the need for surgical
interventions and related adverse events and psychological impact on patients with cervical
cancer precursors. In this clinical trial, the investigators propose to evaluate the
efficacy and safety of photodynamic therapy (PDT) using hexaminolevulinate (HAL) for mild to
moderate-grade CIN (grade 1-2).
Clinical Details
Official title: A Randomized Phase II Dose-finding Study of Hexaminolevulinate (HAL) Photodynamic Therapy (PDT) in Patients With Low/Moderate-grade Cervical Intraepithelial Neoplasia (CIN1 or 2)
Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Primary outcome: Comparison of Lesion Response Rates of Three Different Doses of HAL PDT and Placebo at 3 Months After Treatment.
Secondary outcome: Comparison of HPV Response of Three Different Doses of HAL PDT and Placebo at 3 Months After Treatment.
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Female.
Criteria:
Inclusion Criteria:
- Patients with ectocervical CIN1 or CIN2 as verified by local pathology (biopsy)
obtained within the last month
- Satisfactory colposcopy examination including:
- visibility of entire transformation zone including the squamocolumnar junction
and
- visibility of entire lesion margin
- Negative endocervical os by colposcopy
- Colposcopical visible lesion at visit 2, before treatment
- Patients with an average sized uterine cervix (approximately 27mm diameter) suitable
for application of the Klemcap
- Age 18 or above
- Written informed consent signed
Exclusion Criteria:
- Previous treatment of CIN or invasive disease
- Lesion(s) extending to the vaginal vault
- Atypical glandular cells (AGC) or adenocarcinoma in situ (AIS) on cytology, malignant
cells on cytology or histology or other suspicion of either micro-invasive or
invasive disease
- Suspicion of endocervical disease on colposcopy
- Current severe pelvic inflammatory disease, severe cervicitis, or other severe
gynaecological infection as per colposcopy and clinical examination
- Undiagnosed vaginal bleeding
- History of toxic shock syndrome
- Known or suspected porphyria
- Known allergy to hexaminolevulinate or similar compounds (e. g. methyl aminolevulinate
or aminolevulinic acid)
- Pregnancy, or intention to become pregnant during the study period
- Nursing
- Childbirth or miscarriage within six weeks of enrolment
- Use of heart pacemaker
- Participation in other clinical studies either concurrently or within the last 30
days
- Risk of poor protocol compliance. Patient participation should be considered with
respect to living far away from the hospital, plans for moving to another city/state,
frequent travelling, planning to become pregnant, drug abuse/alcoholic, difficult
working hours, family obligations, other illness (e. g. psychiatric), etc.
- Unwillingness to use adequate birth control (not abstinence) from screening until
last PDT
- Patient is the investigator or any sub-investigator, research assistant, pharmacist,
study coordinator, other staff or relative thereof directly involved in the conduct
of the protocol
Locations and Contacts
University Hospital Hannover, Hannover, Germany
Haukeland University Hospital, Bergen 5021, Norway
Additional Information
Starting date: April 2011
Last updated: August 21, 2014
|